• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by NewAmsterdam Pharma Company N.V.

    5/13/25 11:44:13 AM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NAMS alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    NewAmsterdam Pharma Company N.V.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    N62509109

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    N62509109


    1Names of Reporting Persons

    Capital World Investors
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    6,798,598.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    6,798,598.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,798,598.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.2 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    NewAmsterdam Pharma Company N.V.
    (b)Address of issuer's principal executive offices:

    Gooimeer 2-35, Naarden 1411 DC, Netherlands
    Item 2. 
    (a)Name of person filing:

    Capital World Investors
    (b)Address or principal business office or, if none, residence:

    333 SOUTH HOPE STREET, 55TH FLOOR, LOS ANGELES, CALIFORNIA 90071
    (c)Citizenship:

    N/A
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    N62509109
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    6,798,598 ** **Capital World Investors ("CWI") is a division of Capital Research and Management Company ("CRMC"), as well as its investment management subsidiaries and affiliates Capital Bank and Trust Company, Capital International, Inc., Capital International Limited, Capital International Sarl, Capital International K.K., Capital Group Private Client Services, Inc., and Capital Group Investment Management Private Limited (together with CRMC, the "investment management entities"). CWI's divisions of each of the investment management entities collectively provide investment management services under the name "Capital World Investors." CWI is deemed to be the beneficial owner of 6,798,598 shares or 6.2% of the 109,817,812 shares believed to be outstanding.
    (b)Percent of class:

    6.2  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    6,798,598

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    6,798,598

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Capital World Investors
     
    Signature:Jae Won Chung
    Name/Title:Vice President and Senior Counsel II, Capital Research and Management Company
    Date:05/02/2025
    Get the next $NAMS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NAMS

    DatePrice TargetRatingAnalyst
    12/30/2024$48.00Buy
    H.C. Wainwright
    5/15/2024Buy
    TD Cowen
    3/14/2024$35.00Sector Outperform
    Scotiabank
    1/18/2024$30.00Buy
    Guggenheim
    1/16/2024$37.00Overweight
    Piper Sandler
    10/30/2023$25.00Outperform
    RBC Capital Mkts
    More analyst ratings

    $NAMS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NewAmsterdam Pharma Appoints Adele Gulfo to its Board of Directors

      NAARDEN, the Netherlands and MIAMI, April 17, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ("CVD") with elevated low-density lipoprotein cholesterol ("LDL-C"), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the appointment of Adele Gulfo as an independent director to its Board of Directors. Ms. Gulfo is an established pharmaceutical leader with over three decades of experience in the healthcare industry, distinguished by her expertise in global strategy, operations leadership, and the

      4/17/25 4:01:00 PM ET
      $NAMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Frazier Life Sciences Appoints John Smither and Jim Williams as Senior Advisors

      Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the addition of industry veterans John Smither and Jim Williams, MBA, as Senior Advisors. "John and Jim are seasoned veterans in the field, and each brings a differentiated skill set that will enable us to strengthen our execution across the private and public investment strategies of the firm," said Patrick Heron, Managing Partner at FLS. John has over 25 years of financial experience in the biopharmaceutical industry. Before joining FLS, John served as the Chief Financial Officer of Arcutis Biotherapeutics, Inc., where he led the company's successful initial public offering

      11/19/24 8:00:00 AM ET
      $GNLX
      $NAMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors

      enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced the election of Paul Hastings and Wouter Joustra as new members of its Board of Directors at the Company's 2024 annual meeting of shareholders. Shareholders also reelected incumbent director Lota Zoth. Each will serve a three-year term expiring at the 2027 annual meeting of shareholders. enGene's Board is now comprised of seven members including Richard Glickman (Chairman), Gerald Brunk, Jasper Bos, and Jason Hanson. "We are pleased to welcome Paul and Wouter to our Board of

      5/15/24 4:05:00 PM ET
      $ENGN
      $NAMS
      $NKTX
      $PCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $NAMS
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by NewAmsterdam Pharma Company N.V.

      SCHEDULE 13G/A - NewAmsterdam Pharma Co N.V. (0001936258) (Subject)

      5/15/25 4:58:42 PM ET
      $NAMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by NewAmsterdam Pharma Company N.V.

      144 - NewAmsterdam Pharma Co N.V. (0001936258) (Subject)

      5/15/25 4:40:26 PM ET
      $NAMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by NewAmsterdam Pharma Company N.V.

      SCHEDULE 13G - NewAmsterdam Pharma Co N.V. (0001936258) (Subject)

      5/13/25 11:44:13 AM ET
      $NAMS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NAMS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Operating Officer Kling Douglas F exercised 100,000 units of Ordinary Shares at a strike of $10.00 and sold 100,000 units of Ordinary Shares (SEC Form 4)

      4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)

      5/19/25 4:44:25 PM ET
      $NAMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Officer Audet Juliette Berangere

      4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)

      5/2/25 4:56:15 PM ET
      $NAMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Lange Louis G converted options into 69 units of Ordinary Shares (SEC Form 4)

      4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)

      5/2/25 4:55:45 PM ET
      $NAMS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NAMS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Topper James N bought $25,521 worth of Ordinary Shares (1,135 units at $22.49) (SEC Form 4)

      4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)

      3/28/25 5:36:48 PM ET
      $NAMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Topper James N bought $84,203 worth of Ordinary Shares (4,005 units at $21.02) (SEC Form 4)

      4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)

      3/6/25 5:32:07 PM ET
      $NAMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Business Officer Audet Juliette Berangere bought $17,333 worth of Ordinary Shares (1,104 units at $15.70) (SEC Form 4)

      4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)

      9/30/24 5:22:34 PM ET
      $NAMS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NAMS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by NewAmsterdam Pharma Company N.V.

      SC 13D/A - NewAmsterdam Pharma Co N.V. (0001936258) (Subject)

      12/17/24 5:35:24 PM ET
      $NAMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by NewAmsterdam Pharma Company N.V.

      SC 13D/A - NewAmsterdam Pharma Co N.V. (0001936258) (Subject)

      12/17/24 4:00:47 PM ET
      $NAMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by NewAmsterdam Pharma Company N.V.

      SC 13D/A - NewAmsterdam Pharma Co N.V. (0001936258) (Subject)

      12/17/24 10:28:58 AM ET
      $NAMS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NAMS
    Leadership Updates

    Live Leadership Updates

    See more
    • NewAmsterdam Pharma Appoints Adele Gulfo to its Board of Directors

      NAARDEN, the Netherlands and MIAMI, April 17, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ("CVD") with elevated low-density lipoprotein cholesterol ("LDL-C"), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the appointment of Adele Gulfo as an independent director to its Board of Directors. Ms. Gulfo is an established pharmaceutical leader with over three decades of experience in the healthcare industry, distinguished by her expertise in global strategy, operations leadership, and the

      4/17/25 4:01:00 PM ET
      $NAMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors

      enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced the election of Paul Hastings and Wouter Joustra as new members of its Board of Directors at the Company's 2024 annual meeting of shareholders. Shareholders also reelected incumbent director Lota Zoth. Each will serve a three-year term expiring at the 2027 annual meeting of shareholders. enGene's Board is now comprised of seven members including Richard Glickman (Chairman), Gerald Brunk, Jasper Bos, and Jason Hanson. "We are pleased to welcome Paul and Wouter to our Board of

      5/15/24 4:05:00 PM ET
      $ENGN
      $NAMS
      $NKTX
      $PCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • BioAge Appoints Renowned Cardiologist and Biopharma Entrepreneur Michael H. Davidson, MD, to its Board of Directors

      New board member brings deep expertise in cardiometabolic research, clinical development, and building successful biotech companies BioAge Labs, Inc., ("BioAge"), a clinical-stage biotechnology company developing novel therapies for obesity and metabolic diseases by harnessing the biology of aging, today announced the appointment of Michael Davidson, MD to the company's board of directors. "We are delighted to welcome Michael to BioAge's board of directors," said Kristen Fortney, PhD, CEO and co-founder of BioAge Labs. "His expertise as a physician and researcher in the field of cardiometabolism, deep experience in clinical development, and track record leading multiple successful compa

      4/9/24 8:00:00 AM ET
      $NAMS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NAMS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on NewAmsterdam Pharma with a new price target

      H.C. Wainwright initiated coverage of NewAmsterdam Pharma with a rating of Buy and set a new price target of $48.00

      12/30/24 7:25:48 AM ET
      $NAMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TD Cowen initiated coverage on NewAmsterdam Pharma

      TD Cowen initiated coverage of NewAmsterdam Pharma with a rating of Buy

      5/15/24 7:44:32 AM ET
      $NAMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Scotiabank initiated coverage on NewAmsterdam Pharma with a new price target

      Scotiabank initiated coverage of NewAmsterdam Pharma with a rating of Sector Outperform and set a new price target of $35.00

      3/14/24 7:41:08 AM ET
      $NAMS
      Biotechnology: Pharmaceutical Preparations
      Health Care